Our findings illustrate that FSTL3 could serve as a crucial regulatory factor of the β-Catenin molecular mechanisms, and reflects therefore a promising therapeutic target for anti-metastatic strategies in CRC. The gene discussed is FSTL3; the disease is colorectal carcinoma.